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Introduction
Variant PFAPA affecting adults has been previously
reported but appears to be either extremely rare or sys-
tematically underdiagnosed.
Objectives
To retrospectively analyse patients with symptoms
resembling PFAPA seen in an adult fevers clinic in the
UK.
Patients and methods
Patients were sought from the UK National Amyloidosis
Centre database using PFAPA, fever, pharyngitis, lym-
phadenopathy, and aphthous ulcers as search terms.
Data were collected on demographics, symptoms, inves-
tigations and treatment.
Results
15 patients were identified. 13 were male and all of
white European origin. None gave a family history of
similar symptoms. Current median age is 28.3 years
with median symptom duration of 15 years. 6 patients
presented after the age of 16, and 5 before the age 5. 3
patients reported precipitants for their attacks, in all
cases stress and fatigue. 13 patients reported regular
attacks every 4-6 weeks. Fever was present in 100%;
cervical lymphadenopathy in 93%, pharyngitis in 73%;
oral aphthous ulceration in 40%; abdominal pain in one
third, rash and red eyes in 13%. 13 of 15 patients
reported at least 3 of fever, lymphadenopathy, pharyngi-
tis or aphthous ulceration with attacks.
Sequencing of MEFV, MVK, TNFRSF1A was normal
in all cases. 7 patients provided samples during attacks
with a median CRP 27 mg/L and SAA 205 mg/L. All 15
had normal inflammatory markers when well.
47% underwent tonsillectomy without lasting benefit
in any case. Corticosteroids had been used by 60% with
4 good responses and 4 partial responses; 4 patients
continue on intermittent prednisolone. 14 (93%) have
tried colchicine with 2 complete, 4 good and 6 partial
responses and 12 (86% of exposed) remain on long term
prophylaxis. One patient received anakinra and and 3
tried cimetidine with little effect.
All patients achieved heights and weights within the
normal adult range. 13 of 15 are either in full time edu-
cation or employment. No patients have developed AA
amyloidosis.
Conclusion
Variant PFAPA is seen in adults. In our series 40% pre-
sented after the age of 16 and 33% presented in the typi-
cal age range of less than 5 years with persistent
symptoms into adulthood. Compared to typical child-
hood PFAPA symptoms seem very similar but more
patients are refractory to conventional treatment with
corticosteroids or tonsillectomy. Colchicine given as
long term prophylaxis is the most effective treatment
although complete responses are rare. Despite ongoing
symptoms and elevated CRP and SAA with attacks no
patients have severe social or physical consequences of
their disease.
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